Poly(ADP-Ribose) Polymerase Inhibitors

Poly(ADP-Ribose) Polymerase Inhibitor

Ovarian Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="ID_df480b99-6bdb-4593-9601-9f4c1cdc51d9"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one. The empirical molecular formula for Lynparza is C<span class="Sub">24</span>H<span class="Sub">23</span>FN<span class="Sub">4</span>O<span class="Sub">3</span> and the relative molecular mass is 434.46. It has the following chemical structure:</p><div class="Figure"><a name="id219324315"></a><img alt="chemical structure" src="image-01.jpg"/></div><p>Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility across the physiological pH range.</p><p>Lynparza (olaparib) tablets for oral use contain 100 mg or 150 mg of olaparib. Inactive ingredients in the tablet core are copovidone, mannitol, colloidal silicon dioxide, and sodium stearyl fumarate. The tablet coating consists of hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow, and ferrosoferric oxide (150 mg tablet only).</p></section>

Lynparza

olaparib

olaparib 100 MG Oral Tablet

olaparib 100 MG Oral Tablet [Lynparza]

olaparib 150 MG Oral Tablet

olaparib 150 MG Oral Tablet [Lynparza]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Reimbursement Information

Pharmacy List 

How To Order Lynparza

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Lynparza Enrollment Form 

Enroll in Patient Savings Program - HCP Portal

Enroll in Patient Savings Program - Patient 

AZ&Me Prescription Savings Program - Patient Assistance Program 

AstraZeneca 360 Access - HCP Portal 

Electronic Patient Authorization Form (ePAF)

Lynparza Affodability Brochure 

Other HCP Resources: Ovarian Cancer Advanced or Recurrent

About Lanparza

Getting Started: Ovarian Cancer Advanced or Recurrent

Taking Lynparza: Ovarian Cancer Advanced or Recurrent

Side Effects

Patient Resources

Instructions For Use: Ovarian Cancer Advanced or Recurrent

Enroll in My Lynpraza Support Program 

Patient Brochure: Pancreatic Cancer Metastatic

Patient Brochure: Metastatic Prostate Cancer 

Patient Eligibility: Breast Cancer Early or Metastatic 

About Lynparza: Early Breast Cancer 

Taking Lynpraza: Early Breast Cancer 

Instructions For Use: Pancreatic Cancer Metastatic 

Instructions For Use: Breast Cancer Early or Metastatic 

Instructions For Use: Prostate Cancer Metastatic Castration-Resistant 

About Lynpraza: Prostate Cancer Metastatic Castration-Resistant 